

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Allergic reactions after Pfizer vaccination, casirivimab-imdevimab treatment, post vaccination SARS-CoV-2 infections

Peer reviewed journals featured:

- Observational studies on:
 - Prevalence of allergic reactions after Pfizer vaccination in high allergy risk adults [here](#) and associated commentary [here](#)
 - Risk of hospital admission with COVID-19 among teachers, healthcare workers, and adults of working age in Scotland [here](#)
 - Physical activity changes during and after the first COVID-19 lockdown in England [here](#)
 - Casirivimab-imdevimab for high-risk patients with mild to moderate COVID-19 [here](#)
 - Risk factors and disease profile of post-vaccination SARS-CoV-2 infection [here](#)
- Editorials on:
 - Ronapreve for prophylaxis and treatment of COVID-19 [here](#)
 - Making space for grief [here](#)
- Commentary on global health security and reforming international health regulations [here](#)

Letters and correspondence discussed:

- Links between pandemics and global environmental change [here](#)
- Newly identified cancer among US patients before and through the first year of COVID-19 [here](#)

Pre-peer review articles featured:

- A model of the role of super-spreaders in COVID-19 transmission dynamics [here](#)
- High-throughput SARS-CoV-2 screening for rapid identification of emerging variants [here](#)
- Control interventions, virus mutations and COVID-19 resurgence [here](#)
- Early versus late third trimester maternal Pfizer vaccination [here](#)
- SARS-CoV-2 variant tracking and mitigation in a US university [here](#)

Guidance and reports

- The Therapeutic Goods Administration (TGA) released its COVID-19 vaccine weekly report [here](#)
- Updates to the BMJ Best Practice guide on COVID-19 [here](#)

News and blogs

- The UK will offer a third vaccine dose to severely immunosuppressed people [here](#)
- 80% of young adults in the UK are likely to have antibodies [here](#)
- As COVID-19 hospitalisations of unvaccinated patients soar, US private insurers no longer waiving out-of-pocket costs [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), and [rapid testing](#).